Today we are brining you news of one of the best stories we’ve covered in many a long year of campaigning. Today Hofman-La Roche have announced late stage trials of a brand new antibiotic called Zosurabalpin. If all goes well it could be ready for clinical practice very soon. [1] We’ve been following this for a while now (LSS 1 4 24; The Conversation 5 1 24)[3] : it’s extraordinarily gratifying to see the long process so near to fruition.
There’s much to be excited about at a pure scientific level. Zosuralpin is designed to go after the particularly deadly bacterium Acinobacter baumannii, which can kill up to 50% of its victims. It’s one of those gram negative ones with a double cell wall. Zosurabalpin tackles this in a new way, specifically targeting lipopolysaccharides which the organism uses to maintain the integrity of those walls. For the first time since we entered the world of antibiotics, a gram negative bacteria, the ones which used to really concern the great Professor Garner and the other founders hasa been cornered. But that’s not our main learning point today.
Because Hofman did not develop this alone. Like all modern research it was international and collaborative. The international partner they chose was Harvard University, the oldest in the United States Of America, and one of the best in the world. Until recently. For as astute readers will know, this institution has recently been on the end of a tremendous kicking from President Donald Trump (pictured above with some of his supporters) and other members of his government. We are not certain yet if this will end terminally for Harvard. But at the very least, the time they spend defending themselves from their barbaric assailants would be time better spent developing new antibiotics. It’s worth balancing consequences like that against the savage impulses of the unreasoned, the unlearned and the unintelligent.
#antibiotic resistance #hofman La roche #zosurabalpin #gram negative #medicine #healh #harvard #donald trump #harvard
Learning, Science and Society 